APPLICATION
Application Note
*Optimal dilutions/concentrations should be determined by the researcher.
Application |
Recommended Dilution |
1:1000-1:20000 |
1:100-1:1000 |
Not tested in other applications.
Calculated MW
Positive Control
mouse muscle , rat muscle
Predict Reactivity
Bovine, Dog, Pig, Rhesus Monkey(>80% identity)
PROPERTIES
Form
Liquid
Buffer
0.1M Tris, 0.1M Glycine, 10% Glycerol
Preservative
0.01% Thimerosal
Storage
Store as concentrated solution. Centrifuge briefly prior to opening vial. For short-term storage (1-2 weeks), store at 4ºC. For long-term storage, aliquot and store at -20ºC or below. Avoid multiple freeze-thaw cycles.
Concentration
1 mg/ml (Please refer to the vial label for the specific concentration.)
Antigen Species
Human
Immunogen
Carrier-protein conjugated synthetic peptide encompassing a sequence within the N-terminus region of human Caveolin 3. The exact sequence is proprietary.
Purification
Purified by antigen-affinity chromatography.
Conjugation
Unconjugated
RRID
AB_1949854
Note
For laboratory research use only. Not for any clinical, therapeutic, or diagnostic use in humans or animals. Not for animal or human consumption.
Purchasers shall not, and agree not to enable third parties to, analyze, copy, reverse engineer or otherwise attempt to determine the structure or sequence of the product.
TARGET
Synonyms
caveolin 3 , LGMD1C , LQT9 , MPDT , RMD2 , VIP-21 , VIP21
Cellular Localization
Golgi apparatus membrane; Single-pass membrane protein , Cell membrane; Single-pass membrane protein , Membrane , caveola; Single-pass membrane protein , Golgi apparatus membrane , Cell membrane , Membrane , caveola
Background
This gene encodes a caveolin family member, which functions as a component of the caveolae plasma membranes found in most cell types. Caveolin proteins are proposed to be scaffolding proteins for organizing and concentrating certain caveolin-interacting molecules. Mutations identified in this gene lead to interference with protein oligomerization or intra-cellular routing, disrupting caveolae formation and resulting in Limb-Girdle muscular dystrophy type-1C (LGMD-1C), hyperCKemia or rippling muscle disease (RMD). Alternative splicing has been identified for this locus, with inclusion or exclusion of a differentially spliced intron. In addition, transcripts utilize multiple polyA sites and contain two potential translation initiation sites. [provided by RefSeq]
Database
Research Area
DATA IMAGES
|
GTX109650 WB Image
Rat tissue extract (50 μg) was separated by 12% SDS-PAGE, and the membrane was blotted with Caveolin 3 antibody [N1N2], N-term (GTX109650) diluted at 1:1000.
|
|
GTX109650 WB Image
Mouse tissue extract (50 μg) was separated by 15% SDS-PAGE, and the membrane was blotted with Caveolin 3 antibody [N1N2], N-term (GTX109650) diluted at 1:1000.
|
|
GTX109650 IHC-P Image
Immunohistochemical analysis of paraffin-embedded A549 xenograft, using Caveolin-3(GTX109650) antibody at 1:500 dilution.
Antigen Retrieval: Trilogy™ (EDTA based, pH 8.0) buffer, 15min
|
|
GTX109650 WB Image
The data was published in the journal Hum Mutat in 2011. PMID: 21294223
|
REFERENCE
REVIEW
There are currently no reviews for Caveolin 3 antibody [N1N2], N-term (GTX109650). Be the first to share your experience with this product.